Most common
gastrointestinal endocrine tumor (75% of such
neoplasms)
Presenting
symptoms:
- Gastrointestinal
bleeding
- Abdominal pain
- GI obstruction due
to:
- tumor
growth
- tumor-induced
mesenteric fibrosis
- Symptoms
associated with hormones secreted by the
tumor
- Carcinoid
refers to tumor slow growth (4-5 years between
onset of symptoms and diagnosis) and initial
underestimation of malignant potentialand.
Tumor properties:
Arise from neuroendocrine
cells {neuroendocrine
cells are most common in: the
gastrointestinal tract, pulmonary
bronchi, pancreas}
Tumors are most commonly
found in the appendix, ileum, and rectum
(may be
found anywhere from the stomach to the
rectum)
In the small intestine:
carcinoid tumors -- one of the two most
common malignancies.
90% of carcinoid tumors
derived from enterochromaffin (Kulchitsky
cells) within the gastrointestinal tract
- From a small, primary
tumor, peritoneal and mesenteric spread
induces by fibrotic reactions (causing obstruction,
vascular compromise, intestinal kinking)
Gastric
carcinoid tumor may arise from:
enterochromaffin cells or
histamine-secreting
enterochromaffin-like cells
increased risk
factors for this etiology:
- chronic
atrophic gastritis
- tumorigenesis
due to the combination of
chronic inflammation and
hypergastriemia
associated with atrophic
gastritis.
- achlorhydria
due to:
- pernicious
anemia
- Helicobacter
pylori infection
Carcinoid Syndrome:
Enterochromaffin cells:
- embryologically
related to:
- thyroid C
cells
- adrenal
medullary cells
- melanocytes
secrete many
hormones, causing symptoms of
hormone excess, including:
cutaneous
flushing, diarrhea,
valvular heart disease (endocardial
fibrosis --tricuspid
insufficiency, pulmonary
stenosis, right-sided
heart failure}"classic
triad"
- (less
commonly): wheezing,
paroxysmal hypotension,
telangiectasis (spot
formed on the skin by a
dilated capillary or
terminal artery)
Serotonin:
most common secretory product (tumor
serotonin synthesis from circulating tryptophan)
up to 50% of dietary
tryptophan may be converted to
serotonin by the tumor, leading
insufficient amino acid substrate
for protein synthesis and
conversion to niacin.
Consequently:
patients
may exhibit protein
malnutrition or
mild
pellagra
- (niacin
deficiency -- erythema on
portions of the body
exposed to light,
subsequent dermal
exfoliation;also,
weakness, digestive
disturbance, spinal pain,
convulsions, melancholia)
Diagnosis:
- abdominal pain,
nausea, weight loss, obstruction,
gastrointestinal bleeding
- imaging studies
(CT, barium studies)
- endoscopy
Most
useful diagnostic test:serotonin
metabolite (urinary
5-hydroxyindoleacetic acid
{5-HIAA} concentration -- > 15
mg per day
- plasma and
platelet serotonin levels
- biopsy
- octreotide
scintigraphy (octreotide binds to
type 2 somatostatin receptors
(highly expressed by most
carcinoids)
- Treatment:
tumor
resection (rarely curative due to
metastasis)
loperamide
(Imodium), diphenoxylate
(Lomotil)/atropine
for mild diarrhea:
cholestyramine
(Questran, Questran Light) (following ileal resection)
H1
and H2 receptor
blockers (e.g. diphenhydramine (Benadryl) and
ranitidine (Zantac))-- inhibit
cutaneous flushing.
phenoxybenzamine
(Dibenzyline) -- inhibition of bradykinin
release
methylxanthine
bronchodilators and
glucocorticoids: relief of
dyspnea and wheezing due to
pulmonary carcinoids
cyproheptadine
(Periactin) and methysergide
(Sansert):
relief from diarrhea
note that methysergide
can promote fibrosis
(similar to that caused
by the tumor)
Octreotide:
potent inhibitor of carcinoid
hormone secretion. Effective in:
- treating
life-threatening
carcinoid syndrome
manifestations, e.g.:
- hypotension
with resulting angina.
- Transient
exacerbation due to
general anesthesia for
example.
Systemic chemotherapy:
streptozocin (Zanosar),
fluorouracil (5-FU), cyclophosphamide (Cytoxan),
dacarbazine (DTIC) and doxorubicin (Adriamycin)
-- best response:
combination
of doxorubicin (Adriamycin) and
streptozocin (Zanosar) {tumor
regression in 40% of
patients}
IFN-alpha
|